WILM'S TUMOUR GENE (WT1) EXPRESSION IN PEDIATRIC PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA.
(Abstract release date: 05/19/16)
EHA Library. Mikhael N. 06/09/16; 134501; PB1601
Dr. Neveen Mikhael
Contributions
Contributions
Abstract
Abstract: PB1601
Type: Publication Only
Background
The Wilms Tumor gene (WT1) encodes a transcription factor involved in kidney development and malignancy. WT1 expression in a subpopulation of early CD34+ cells has suggested its involvement in hematopoiesis. Wilms' tumor gene 1 (WT1) is overexpressed in the majority of adult acute leukemias and has been identified as an independent adverse prognostic factor. Acute lymphoblastic leukemia (ALL) is the most common childhood cancer representing 23% of pediatric cancers. Previous reports show controversial results regarding utility of WT1 expression as a prognostic and MRD marker in childhood ALL.
Aims
The aim of this work was to study the impact of WT-1 gene expression at diagnosis in a group of Egyptian children with ALL relating it to prognosis, also determine the efficacy of using this marker in minimal residual disease monitoring as compared to standard immunophenotyping methods.
Methods
This study was conducted on 70 children with newly diagnosed as ALL, assessment of WT-1 gene was done by real time PCR in BM samples at diagnosis and at day 28 of treatment.
Results
Positive WT-1 gene expression was positive in 48 cases (68.6%) and negative expression in 22 cases (31.4%). There was statistically significant difference between positive and negative WT-1 gene expression groups regarding immunophenotyping, where all cases that showed aberrant expression of CD13 and CD33 were positive for WT1(p=0.028). There was significant correlation between WT1 expression at diagnosis and response to induction chemotherapy, 12/48 cases positive for WT-1 gene expression, showed MRD at d 28 while in negative WT1 group none were positive for MRD (p=0.029). There was a correlation between WT1 level expression at day 28 and MRD as detected by immunophenotyping. (p=0.021).
Conclusion
WT-1 gene expression is important prognostic factor related to response to therapy as defined by d28 MRD. WT1 level can be used as MRD marker by itself for follow up and comparable to standard immunophenotypic methods.
Session topic: E-poster
Keyword(s): Acute lymphoblastic leukemia, MRD, WT1
Type: Publication Only
Background
The Wilms Tumor gene (WT1) encodes a transcription factor involved in kidney development and malignancy. WT1 expression in a subpopulation of early CD34+ cells has suggested its involvement in hematopoiesis. Wilms' tumor gene 1 (WT1) is overexpressed in the majority of adult acute leukemias and has been identified as an independent adverse prognostic factor. Acute lymphoblastic leukemia (ALL) is the most common childhood cancer representing 23% of pediatric cancers. Previous reports show controversial results regarding utility of WT1 expression as a prognostic and MRD marker in childhood ALL.
Aims
The aim of this work was to study the impact of WT-1 gene expression at diagnosis in a group of Egyptian children with ALL relating it to prognosis, also determine the efficacy of using this marker in minimal residual disease monitoring as compared to standard immunophenotyping methods.
Methods
This study was conducted on 70 children with newly diagnosed as ALL, assessment of WT-1 gene was done by real time PCR in BM samples at diagnosis and at day 28 of treatment.
Results
Positive WT-1 gene expression was positive in 48 cases (68.6%) and negative expression in 22 cases (31.4%). There was statistically significant difference between positive and negative WT-1 gene expression groups regarding immunophenotyping, where all cases that showed aberrant expression of CD13 and CD33 were positive for WT1(p=0.028). There was significant correlation between WT1 expression at diagnosis and response to induction chemotherapy, 12/48 cases positive for WT-1 gene expression, showed MRD at d 28 while in negative WT1 group none were positive for MRD (p=0.029). There was a correlation between WT1 level expression at day 28 and MRD as detected by immunophenotyping. (p=0.021).
Conclusion
WT-1 gene expression is important prognostic factor related to response to therapy as defined by d28 MRD. WT1 level can be used as MRD marker by itself for follow up and comparable to standard immunophenotypic methods.
Session topic: E-poster
Keyword(s): Acute lymphoblastic leukemia, MRD, WT1
Abstract: PB1601
Type: Publication Only
Background
The Wilms Tumor gene (WT1) encodes a transcription factor involved in kidney development and malignancy. WT1 expression in a subpopulation of early CD34+ cells has suggested its involvement in hematopoiesis. Wilms' tumor gene 1 (WT1) is overexpressed in the majority of adult acute leukemias and has been identified as an independent adverse prognostic factor. Acute lymphoblastic leukemia (ALL) is the most common childhood cancer representing 23% of pediatric cancers. Previous reports show controversial results regarding utility of WT1 expression as a prognostic and MRD marker in childhood ALL.
Aims
The aim of this work was to study the impact of WT-1 gene expression at diagnosis in a group of Egyptian children with ALL relating it to prognosis, also determine the efficacy of using this marker in minimal residual disease monitoring as compared to standard immunophenotyping methods.
Methods
This study was conducted on 70 children with newly diagnosed as ALL, assessment of WT-1 gene was done by real time PCR in BM samples at diagnosis and at day 28 of treatment.
Results
Positive WT-1 gene expression was positive in 48 cases (68.6%) and negative expression in 22 cases (31.4%). There was statistically significant difference between positive and negative WT-1 gene expression groups regarding immunophenotyping, where all cases that showed aberrant expression of CD13 and CD33 were positive for WT1(p=0.028). There was significant correlation between WT1 expression at diagnosis and response to induction chemotherapy, 12/48 cases positive for WT-1 gene expression, showed MRD at d 28 while in negative WT1 group none were positive for MRD (p=0.029). There was a correlation between WT1 level expression at day 28 and MRD as detected by immunophenotyping. (p=0.021).
Conclusion
WT-1 gene expression is important prognostic factor related to response to therapy as defined by d28 MRD. WT1 level can be used as MRD marker by itself for follow up and comparable to standard immunophenotypic methods.
Session topic: E-poster
Keyword(s): Acute lymphoblastic leukemia, MRD, WT1
Type: Publication Only
Background
The Wilms Tumor gene (WT1) encodes a transcription factor involved in kidney development and malignancy. WT1 expression in a subpopulation of early CD34+ cells has suggested its involvement in hematopoiesis. Wilms' tumor gene 1 (WT1) is overexpressed in the majority of adult acute leukemias and has been identified as an independent adverse prognostic factor. Acute lymphoblastic leukemia (ALL) is the most common childhood cancer representing 23% of pediatric cancers. Previous reports show controversial results regarding utility of WT1 expression as a prognostic and MRD marker in childhood ALL.
Aims
The aim of this work was to study the impact of WT-1 gene expression at diagnosis in a group of Egyptian children with ALL relating it to prognosis, also determine the efficacy of using this marker in minimal residual disease monitoring as compared to standard immunophenotyping methods.
Methods
This study was conducted on 70 children with newly diagnosed as ALL, assessment of WT-1 gene was done by real time PCR in BM samples at diagnosis and at day 28 of treatment.
Results
Positive WT-1 gene expression was positive in 48 cases (68.6%) and negative expression in 22 cases (31.4%). There was statistically significant difference between positive and negative WT-1 gene expression groups regarding immunophenotyping, where all cases that showed aberrant expression of CD13 and CD33 were positive for WT1(p=0.028). There was significant correlation between WT1 expression at diagnosis and response to induction chemotherapy, 12/48 cases positive for WT-1 gene expression, showed MRD at d 28 while in negative WT1 group none were positive for MRD (p=0.029). There was a correlation between WT1 level expression at day 28 and MRD as detected by immunophenotyping. (p=0.021).
Conclusion
WT-1 gene expression is important prognostic factor related to response to therapy as defined by d28 MRD. WT1 level can be used as MRD marker by itself for follow up and comparable to standard immunophenotypic methods.
Session topic: E-poster
Keyword(s): Acute lymphoblastic leukemia, MRD, WT1
{{ help_message }}
{{filter}}